World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT03068468
Date of registration: 27/02/2017
Prospective Registration: Yes
Primary sponsor: Biogen
Public title: Study of BIIB092 in Participants With Progressive Supranuclear Palsy PASSPORT
Scientific title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy
Date of first enrolment: June 1, 2017
Target sample size: 490
Recruitment status: Terminated
URL:  https://clinicaltrials.gov/show/NCT03068468
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).  
Phase:  Phase 2
Countries of recruitment
Australia Austria Canada France Germany Greece Italy Japan
Korea, Republic of Russian Federation Spain United Kingdom United States
Contacts
Name:     Medical Director
Address: 
Telephone:
Email:
Affiliation:  Biogen
Key inclusion & exclusion criteria

Key Inclusion Criteria:

- Participants with probable or possible PSP

- Able to ambulate independently or with assistance

- Able to tolerate MRI

- Have reliable caregiver to accompany participant to all study visits

- Score greater or equal to 20 on the Mini Mental State Exam (MMSE) at screening

- Participant must reside outside a skilled nursing facility or dementia care facility
at the time of screening and admission to such a facility must not be planned

Key Exclusion Criteria:

- Presence of other significant neurological or psychiatric disorders

- Diagnosis of amyotrophic lateral sclerosis (ALS) or other motor neuron disease

- History of early, prominent rapid eye movement (REM) sleep behavior disorder

- History of or screening brain MRI scan indicative of significant abnormality

- Known history of serum or plasma progranulin level less than one standard deviation
below the normal patient mean for the laboratory performing the assay

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply



Age minimum: 41 Years
Age maximum: 86 Years
Gender: All
Health Condition(s) or Problem(s) studied
Supranuclear Palsy, Progressive
Intervention(s)
Drug: BIIB092
Drug: Placebo
Primary Outcome(s)
Change From Baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at Week 52 [Time Frame: Baseline, Week 52]
Percentage of Participants with Death, Serious Adverse Events (SAEs), Adverse Events Leading to Discontinuation, and Grade 3 and 4 Laboratory Abnormalities [Time Frame: Up to 52 Weeks]
Secondary Outcome(s)
Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Disease Severity (RBANS) Scale at Week 52 [Time Frame: Baseline, Week 52]
Change From Baseline in Schwab and England Activities of Daily Living (SEADL) Scale Score at Week 48 [Time Frame: Baseline, Week 48]
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Week 52 [Time Frame: Baseline, Week 52]
Change From Baseline in Progressive Supranuclear Palsy Quality of Life Scale (PSP-QoL) Score [Time Frame: Baseline, Week 52]
Clinical Global Impression of Change (CGI-C) Scale Score [Time Frame: Week 52]
Change From Baseline in Letter-Number Sequencing Test at Week 48 [Time Frame: Baseline, Week 48]
Change From Baseline in Movement Disorder Society (MDS)-sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II at Week 52 [Time Frame: Baseline, Week 52]
Change From Baseline in Phonemic Fluency Test Score at Week 48 [Time Frame: Baseline, Week 48]
Percent Change from Baseline of Brain Volumes as Determined by MRI [Time Frame: Up to Week 52]
Change From Baseline in Color Trails Test at Week 48 [Time Frame: Baseline, Week 48]
Change From Baseline in Montreal Cognitive Assessment (MoCA) Score at Week 48 [Time Frame: Baseline, Week 48]
Number of Participants with Drug Antibodies (anti-BIIB092) in Serum [Time Frame: Up to Week 52]
Secondary ID(s)
2016-002554-21
251PP301
CN002-012
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey